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Inhibition of phorbol 12,13-dibutyrate-induced protein kinase C (PKC) activity from rat midbrain, anterior pituitary and a number of other tissues, 
as well as COS 7 cells, was studied in vitro. In anterior pituitary, Ca’+-independent activity was notably resistant o H7 but sensitive to staurosporine 
and Ro 31-8220. All Ca”-dependent activity was sensitive to these three inhibitors. Mezerein and 1,2-dioctanoyl-sn-glycerol also activated this 
H7-insensitive PKC from anterior pituitary. The distribution of this activity, prominently expressed in pituitary and perhaps also lung, and its 
characteristic resistance to H7 but not other inhibitors, does not obviously correlate with that of any of the wellcharacterised PKCs, and may reflect 
either a novel or a modified isoform. 
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1. INTRODUCTION 
Protein kinase C (PKC) was originally defined as a 
phospholipid- and calcium-dependent serine/threonine 
protein kinase that could be activated by diglycerides 
and tumour-promoting phorbol esters [1,2]. It is now 
known that at least 10 structurally different isoforms of 
PKC exist, which may be subdivided into three groups 
[3]. The cPKCs (a, PI, /?I1 and y) all require Ca2+ for 
activation, while the nPKCs (6, E, q, 0) and the aPKCs 
(c and 1) all lack the proposed Ca2+ binding domain and 
are active in the absence of Ca2+ [3]. Each isoform has 
been shown to exhibit a unique tissue distribution [4,5]; 
some (for example s> being widespread [6], while others, 
like 8, are highly tissue specific [7], suggesting that each 
isoform may play a different physiological role. This is 
supported by studies showing that PKC isoforms vary 
in their biochemical properties, such as activation by 
diglycerides and phorbol esters [8], phospholipid de- 
pendence [9] and substrate specificity [IO]. PKC c, for 
example, is reported not to be activated by phorbol 
esters and diglycerides [I 1,121, as this isoform (like 1) 
lacks one of the cysteine-rich regions that are thought 
to constitute the high-affinity phorbol binding domain 
[13]. It is therefore possible that particular PKC 
isoforms may be activated in response to different cellu- 
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lar stimuli and may phosphorylate distinct target pro- 
teins. 
In this study, the effect of the inhibitors, stauro- 
sporine [14], H7 [15] and Ro31-8220 [16], on cytosolic 
PKCs partially purified from rat midbrain, anterior pi- 
tuitary gland and a variety of other tissues, was investi- 
gated. The anterior pituitary was assessed because our 
studies there on the role of PKC in stimulus-secretion 
coupling revealed participation of a form of PKC that 
is unusually resistant to H7 but not other PKC inhib- 
itors [17,18]. Midbrain is reported to contain all of the 
well-characterised PKC isoforms [19], while the other 
tissues were investigated because of their reported en- 
richment in particular isoforms. PKC activity evoked 
by the diterpenes phorbol 12,13-dibutyrate (PDBu) and 
mezerein, and by the synthetic diglyceride, 1,2-dioc- 
tanoyl-sn-glycerol (DOG), was studied in cytosol from 
anterior pituitary and midbrain since certain PKC ac- 
tivators have been shown to differ in their ability to 
activate individual PKC isoforms in vitro [8] and vari- 
ous PKC-mediated processes in vivo [20-221. 
2. MATERIALS AND METHODS 
2.1. Cytosolic PKC activity assay 
Partially purified cytosolic PKC activity was determined as the 
PDBu-induced histone III-S thiophosphorylation in the presence of 
phosphatidylserine (PS). All of the activity measured was PS depend- 
ent, as it was absent when PS was replaced by phosphatidylcholine 
which is unable to act as a cofactor in PKC activation [2]. A mixed 
micelle assay was used in this study to enable the Ca2’-dependent and 
-independent activity to be. analysed separately, as PKC activation is 
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obligatorily dependent on phor~~digly~~de activators under these 
conditions [23]. The methods used were modified from those in 124,251 
and have been briefly described previously [18]. Tissue from male 
Wistar rats (230-350 g) was homogenised in 2 ~01s. of 20 mM Tris-HCl 
(pH 7.5) containing 50 mM 2-mercaptoethanol, 2 mM EDTA, 1 mM 
phenylmethylsulphonyl f uoride (Sigma), 0.01% (w/v) leupeptin 
(Sigma) and 20 PM rruns-epoxysuccinyl+leucylamido (eguanidino) 
butane (E64) (Sigma). Alternatively, COS 7 cells (cultured at 37°C in 
DMEM with 10% normal calf serum under 5% CO,) were washed in 
Ca2’/MgZ’-free Hank’s salt solution and then harvested from tissue 
culture flasks by scraping into ice-cold homogenization buffer. The 
suspension was then homogenized using a Ystral polytron homoge- 
nizer (Scientific International Industries Ltd., Loughborough, Leics., 
UK). The homogenate was centrifuged (16,000 x g, 20 min, 4’C) and 
the supematant was collected and re~nt~fug~ (16,000 x g, 5 min, 
4*C). The supernatant from the second spin was taken to represent 
cytosol and was partially purified by loading onto 0.5 ml (cells and 
pituitaries) or 1.5 ml (tissues) diethylaminoethyi cellulose (DE52; 
Whatman International Ltd., Maidstone, Kent, UK) in a Bio-Rad 
Poly-Prep chromatography column (Bio-Rad Laboratories, 
Richmond, CA, USA) at 4°C. The matrix was then washed with 6 
column ~01s. of homogenization buffer before the partially purified 
PKC was eluted with 3 column ~01s. of buffer containing 150 mM 
NaCl. Cytosolic PKC activity was then measured in an assay mixture 
(total volume 100 ~1) containing, unless otherwise stated, (final con- 
centrations): 10 mM MgCl,, 2OOpgiml PS (sodium salt) (Lipid Prod- 
ucts, Nutfield, Surrey, UK), 0.04% Nonidet P-40 (Calbiochem, Nova- 
b&hem, Nottingh~, UK), 1.25 mg/mI histone III-S (Sigma), 50pM 
y-[?S]ATP (NEN) (0.18 ~Ci/tu~), 1 FM PDBu (LC Services Corp., 
Scientific Marketing Associates, Bamet, UK) and 25 ~1 cytosol. F’S 
vesicles were prepared by drying the lipid from chlorofo~methanol 
under a stream of N,. The subsequent film of PS was scraped into 20 
mM Tris-HCl (pH 7.5) with 0.5 mM EGTA, sonicated, then 0.16% 
Nonidet P-40 was added. The mixture was vortexed before use. Assay 
tubes also contained either 6OOpM CaCl, (100pM free Ca”) or 5 mM 
EGTA (less than 3 nM free Ca*+) and inhibitors at various concentra- 
tions. All assay components and drugs were dissolved in 20 mM 
Tris-HCl (PH 7.5) with 0.5 mM EGTA except the substrate, histone 
III-S, which was dissolved in the MgCl, solution. Reactions were 
started by the addition of enzyme, incubated at 30°C for 15 min and 
stopped by quenching with 20,&0.1 M ATP in 0.1 M EDTA (pH 7.0). 
50 ~1 of the quenched reaction mixture was spotted onto a 4 cm* piece 
of P-81 cellulose phosphate ion-exchange chromatog~phy paper 
(Mayan Intonational Ltd.) then washed (3 x 10 ml, 2 min, room 
temperature) in 75 mM H,PO,, dried and counted by liquid scintilla- 
tion. 
2.2. PKC activators and inhibitors 
PDBu, mezerein (LC Services Corp.), DOG (Sigma), staurosporine 
(Calbiochem) and Ro31-8220 (Roche Products Ltd. Welwyn Garden 
City, UK) were made up as l-10 mM stock solutions in dimethylfor- 
mamide (DMF). With the exception of DOG (freshly prepared), all 
of these reagents were used from stocks maintained at -20°C. H7 (LC 
Services Corp.) was dissolved in distilled water (10 mM) and used from 
aliquots maintained at -2O’C. 
2.3. Placation of PKC a and p 
PKC a and /3 were more extensively purified from tat brain by 
hy~oxylapatite (Biogel HT, Bio-Rad Laboratories) chromatography 
following DEAE-cellulose treatment of tissue extracts as described in 
[26]. Following PAGE the presence of specific immunoreactivity for 
a and p PKC, respectively, in these preparations was confirmed with 
specific antipeptide antisera for these isoforms [27]. The specific activ- 
ities of the preparations used were 17.8 mu/ml and 36.6 mU/ml for 
PKC a and p, respectively. 
2.4. Data analysis 
Basal activity with PS alone (at appropriate inhibitor concentra- 
tions) was subtracted from the inhibitor curves in the absence/presence 
200 
of Ca”. A normal&d as~metric sigmoid Hill curve was fitted to the 
Ca2’-independent evoked activity and subtracted from the evoked 
activity values obtained in the presence of Ca’+. A normal&d curve 
was then similarly fitted to the resulting values for Ca”-dependent 
activity. Curve fitting was carried out using the iterative error- 
weighted curve fitting program, P.fit (Biosoft, Cambridge, UK). 
3. RESULTS 
3.1. Effects of different PKC inhibitors 
Both Ca2’-independent and -dependent PKC activity 
was elicited in midbrain and anterior pituitary cytosol 
in a condensation-de~ndent manner by PDBu (10 
nM-3 PM). The response to 1 PM PDBu was almost 
maximal in each case with typical values for Caz+-de- 
pendent and -independent activity in midbrain of 
5.6 k 0.4 and 12.0 ?I 0.3 x lo3 dpm per mg tissue equiv- 
alent. The corresponding values for anterior pituitary 
were 3.0 + 1.3 and 3.6 It 1.9 x lo3 dpm per mg tissue 
equivalent. The 1 ,uM PDBu-induced PKC activity from 
COS 7 cells was entirely Ca2’-dependent, which is con- 
sistent with reports that PKC CI is the only phorbol- 
activated isoform present in these cells [28]. 
Table I shows IC, values (the con~ntration required 
to inhibit 50% of the effect} for inhibition of PKC activ- 
ity from rat midbrain, anterior pituita~ and COS 7 cells 
by H7, staurosporine and Ro31-8220. In each case, his- 
tone III-S thiophosphorylation was stimulated by 
PDBu (1 PM). In midbrain, staurosporine, Ro-31-8220 
and H7 all inhibited both Ca2’-dependent and -inde- 
pendent activity with similar I&, values. The potencies 
of all three inhibitors on activity from COS 7 cells were 
similar to those obtained in midbrain. This is in contrast 
to in anterior pituitary where, although staurosporine 
Table I 
Effects of H7, staurosporine and Ro31-8220 on PRBu-indu~ PKC 
activity from midbrain, anterior pituitary and COS 7 cells 
Tissue IC, 01M) 
H7 Stauro- 
sporine 
Ro3 I-8220 
Midbrain Ca*+- 28 f 5 0.12 + 0.01 0.18 f 0.03 
-independent 
Caz+- 22 t 1 0.10 + 0.04 0.19 + 0.01 
-dependent 
Pit~tary Ca2+- 145 -I 38 0.10 + 0.04 0.34 + 0.07 
-independent 
Ca2+- 25 f 4 0.12 * 0.05 0.14 z!z 0.03 
-dependent 
COS 7 cells Ca*+- 362 11 0.17 ? 0.03 0.26 & 0.05 
-dependent 
PS-dependent histone III-S phosphorylation was evoked by 1 PM 
PDBu at varying concentrations of inhibitor and the IC,, value deter- 
mined (means + S.E.M.) (4 zz n s 6). Ca’+-independent activity was 
measured in the presence of EGTA (5 mM) while Ca”-dependent 
activity was calculated from the activity in the presence of calcium (100 
PM free). There was no detectable Ca*‘-independent activity in COS 
7 cells. 
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and Ro3 l-8220 inhibited Ca’+-dependent and -inde- 
pendent activity with similar potencies, H7 was consid- 
erably less potent on Ca2’-independent activity (I&, 
values of 148 f: 38 and 25 f 4pM for Ca2’-independent 
and -dependent, respectively). 
3.2. Regional differences in the inhibition of PKC 
Table II shows the ICso values for H7 inhibition of 
PDBu-induced PKC activity from a variety of tissues 
and cell lines. In the majority of the regions studied, 
there was no difference in the potency of H7 on the 
Ca”-dependent and -independent activity evoked by 
PDBu, the ICsO values varying between 10 and 45 PM. 
However, in cytosol from anterior pituitary, and per- 
haps to a lesser extent lung, the Ca2’-independent, but 
not -dependent, activity was relatively insensitive to H7. 
3.3. The effect of different PKC activators on H7-resis- 
tant activity 
The inhibition by H7 of activity evoked by either 
PDBu (1 PM), mezerein (1 PM) or DOG (1 mM), in 
midbrain and pituitary preparations is shown in Figs. 
1 and 2. At these concentrations both Ca2’-dependent 
and -independent PKC activity was almost maximal in 
anterior pituitary (data not shown). In midbrain, H7 
was equipotent on Ca”-dependent and -independent 
activity evoked by PDBu and DOG (IC,, values in the 
range 22-33 PM) (Fig. la and c), although the Ca2’- 
dependent activity induced by mezerein was somewhat 
more sensitive to H7 (I& value 6 f 1 ,LM) (Fig. lb). 
This is as we have previously reported [29] and is likely 
to be due to a form of cPKC that is more potently 
inhibited by H7, retaining rigorous Ca2’-dependence 
when activated by mezerein. However, in anterior pitu- 
itary, PDBu, mezerein and DOG evoked Ca”-inde- 
pendent activity that was insensitive to H7 (I& values 
145 f 38, 148 f 21 and 118 f 42,uM, respectively) (Fig. 
2a). The Ca2+-dependent activity induced by PDBu and 
DOG in anterior pituitary cytosol was H7 sensitive 
Table II 
Effect of H7 on cytosolic PKC activity from various sources 
Sources IGO 01M) 
Ca2’-independent Ca2’-dependent activity 
activity 
Midbrain 
Pituitary 
cos 7 cells 
Cerebellum 
Lung 
Spleen 
Liver 
28 f 5 22rt: 1 
148 k 38 25 f 4 
N.D. 36k 11 
38f 15 34 f 9 
87 + 37 39 + 6 
19 + 3 25 + 3 
15+11 N.D. 
PS-dependent histone HIS phosphorylation was evoked by 1 PM 
PDBu at various concentrations of H7 in the presence (100 PM free) 
or absence (< 3 nM) of calcium and the IC,O value determined. Values 
are means * S.E.M. (4 < n G 6). N.D., not detectable. 
(IC,, values 25 f 4, 21 f 10 PM) (Fig. 2b). In anterior 
pituitary, maximal activity was evoked by mezerein (1 
PM) even in the absence of Ca’+, and thus no separate 
determination of the potency of H7 on Ca2+-dependent 
mezerein-evoked activity could be made. The maximal 
amount of PKC activity was similar with both PDBu 
and mezerein, the only difference being the Ca2+-de- 
pendence, which is consistent with previous reports that 
some activators, like some substrates, do not display 
rigorous Ca2’ dependence [8,9]. 
3.4. Inhibition by H7 of a and /3 isoforms 
Since the cPKC isoforms show some activity in the 
absence of Ca2+ [8], and there is evidence that auto- 
phosphorylation of PKC p may diminish its Ca2+ de- 
pendence [30], it was possible that the H7-resistant 
Ca”-independent activity could be due to PKC a or p 
being activated in the absence of Ca2’. The potency of 
H7 was therefore determined, in the absence of Ca2’, on 
PKC a and B, more extensively purified from rat brain 
by hydroxylapatite (HAP) chromatography. Small 
quantities of other isoforms may be present within these 
preparations, but it was evident that both the PKC a 
and PKC p activities in the absence of Ca2’ were sensi- 
tive to H7, with I(& values of 35 + 16 and 40 f 7 ,uM, 
respectively (Fig. 3). 
4. DISCUSSION 
In this study, the effects of catalytic domain inhibitors 
on PKC activity partially purified from several tissue 
and cell line sources have been compared. Stauro- 
sporine, H7 and Ro31-8220 are ATP-competitive inhib- 
itors [14-163 but this study has shown differences in 
their inhibition properties. There is evidence to suggest 
that, although they all bind close to the ATP site, the 
precise sites of action appear to be different. H7 has 
been shown to compete kinetically with ATP [31] but 
only partially protects the ATP site against denatura- 
tion by covalent chemical reagents [32], and this inhibi- 
tor displaces Ro31-8220-sensitive the binding of 
[3H]N,N-dimethyl staurosporine only at high concentra- 
tions [33]. Staurosporine was equipotent on the Ca2’- 
dependent and -independent activity from midbrain, pi- 
tuitary and COS 7 cells. This compound is a potent 
PKC inhibitor but lacks selectivity, also inhibiting other 
serine/threonine kinases, as well as some tyrosine ki- 
nases [34]. The more selective PKC inhibitor, Ro 31- 
8220 [16], showed a small variation in potency on PKC 
activity from the sources tested, which is consistent with 
a recent report [35] that Ro31-8220 shows modest dif- 
ferences in potency between PKC isoforms. The only 
marked differences in potency, however, occurred with 
H7; the Ca”-independent activity from anterior pitui- 
tary being particularly insensitive to this inhibitor 
(Table II). This is consistent with previous reports from 
this laboratory that a number of pituitary cell functions 
201 
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Fig. 1. Inhibition by H7 of (a) PDBu-, (b) mezerein- and (c) DOG- induced PKC activity from midbrain. Histone III-S thiophosphorylation i duced 
by (a) PDBu (1 PM), (b) mezerein (1 PM) or (c) DOG (1 mM) was measured at various concentrations of H7 in the presence of either 100 PM 
or c 3 nM free Ca*+. All points are means + S.E.M. (4 =Z n c 6). IC,, values for Ca*+-independent activity were 28 f 5, 28 f 4 and 33 ?r 13 PM 
for PDBu, mezerein and DOG, respectively. Activity in the presence of Ca2’ was stripped for Ca*‘-independent activity as described in section 
2, and the IC, values obtained were 22 f 1, 6 k 1 and 31 f 5 for PDBu, mezerein and DOG, respectively. (0) Ca2+-independent activity; (m) 
Ca*‘-dependent activity. 
are mediated by an H7-resistant form of PKC [17,18], containing H7-resistant activity (Table II). Pituitary 
and from other laboratories describing phorbol ester- cells have been shown by immunoblotting to contain 
induced responses that are inhibited by staurosporine PKC CI, /?, 6, E and 6 but not the y or q isoforms [40], 
but not H7 [36,37]. When the I&, values for H7 were while lung has been reported to contain the nPKCs 6, 
determined for a number of different tissues, there was c and r,r but not E [5,41]. However, Ca2+-independent 
little variation in potency on the Ca’+-dependent activ- activity from thalamus and spleen, both containing 
ity from all the tissues tested, including COS 7 cells large amounts of PKC 6 [19,42], showed no evidence of 
where PKC c1 is the only phorbol--responsive isoform H7-resistant activity (Table II), and this isoform, puri- 
present [28], spleen (containing some tl but predomi- fied from 3Yl cells, has been reported to be sensitive to 
nantly B of the cPKCs) [38], and cerebellum (particu- H7 [43]. PKC E, although present in pituitary, is absent 
larly rich in cPKC r) [38]. This is consistent with previ- from lung [5] and has previously been shown to be H7 
ous evidence that the cPKCS do not vary in their re- sensitive [44]. Furthermore, there is evidence that PKC 
sponse to H7 [39]. The ICsO values for Ca2’-independent E is not able to efficiently phosphorylate histone [44,45]. 
activity, however, showed wide variations, with pitui- The other isoform common to both tissues, PKC c, is 
tary and perhaps lung (but not the other sources tested) reported not to be activated by phorbol esters [l 1,121 
202 
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Fig. 2. Inhibition by H7 of (a) PDBu-, (b) mezerein- and (c) DOG- induced PKC activity from anterior pituitary. Histone III-S thiophosphorylation 
induced by (a) PDBu (1 PM), (b) mezerein (1 PM) or (c) DOG (1 mM) was measured at various concentrations of H7 in both the presence of either 
100 PM or c 3 nM free Ca”. AI1 points are means + S.E.M. (4 c n s 6). I&, values for Ca “-independent activity were 145 + 38, 148 ?r 1 and 
118 f 42 PM for PDBu, mezerein and DOG, respectively. Activity in the presence of Ca” was stripped for Ca’+-independent activity as described 
in section 2, and the IC,, values obtained were 25 f 4 and 21 + 10 PM for PDBu and DOG, respectively. Mezerein induced no additional activity 
in the presence of Ca*+. (0) Ca2’-independent activity; (m) Ca’+-dependent activity. 
and is also present in COS 7 cells [46] which showed no 
PDBu- induced Ca*‘-independent activity. Thus the tis- 
sue distribution of this H7-resistant PDBu-induced ac- 
tivity clearly does not correspond to any of these nPKC 
or aPKC isoforms. 
PKC activators other than PDBu have been shown 
to elicit quite different effects on 45Ca2’ influx through 
L-type Ca2+ channels in the anterior pituitary compared 
to the GH, cell line [20,21], and to differ in their ability 
to activate individual PKC isoforms in vitro [8]. This 
study has shown that both mezerein and DOG were also 
able to evoke H7-insensitive Ca*‘-independent PKC ac- 
tivity in pituitary cytosol (Fig. 2), consistent with the 
ability of these compounds to selectively activate an 
H7-resistant form of PKC which facilitates Ca2’ entry 
through L channels [23,24]. It has been reported that 
certain diterpenes are capable of activating cPKCs in 
the absence of Ca” [8], but there is evidence that DOG 
is only able to activate PKC c1 and possibly j? in the 
presence of Ca*+ ([47] and Johnson et al., unpublished 
observations). Thus the ability of DOG to elicit the 
H7-resistant kinase activity suggests that this is not due 
to Ca*‘-independent cPKC activity. This was further 
substantiated when the inhibition by H7 of PKC c1 and 
/3 purified from rat brain by HAP chromatography were 
studied in the absence of Ca*+ and shown to be of nor- 
mally high potency. 
Thus it appears that the H7-insensitive kinase, found 
in pituitary and perhaps lung does not correspond to 
any of the well-characterised Ca*+-independent iso- 
203 
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Fig. 3. Inhibition by H7 of PKC a and /I purified from rat brain by 
HAP chromatography. PDBu (1 PM)-evoked PKC activity was meas- 
ured in the presence of < 3 nM free Ca2’ with varying concentrations 
of H7. All points are means + S.E.M. (n = 4). (0) PKC a; (m) PKC 
/3. I&, values for PKC a and /I were 35 f 16 and 40 f 7 FM, respec- 
tively. 
forms and is not a cPKC activated in the absence of 
Ca*+. This activity may represent one of the incom- 
pletely characterised isoforms, such as PKC 8 or A; 
alternatively it may be a modified form of one of the 
known PKCs or perhaps a novel PKC isoform. 
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